Journal of Psychiatric Practice, published by Lippincott Williams & Wilkins, is a premier journal dedicated to advancing the field of psychiatry and mental health. With a focus on evidence-based clinical practice, the journal has been a respected resource since its inception, providing a platform for a wide range of articles, including original research, reviews, and case reports from 1997 to the present. As of 2023, it holds a Q3 ranking in Psychiatry and Mental Health, reflecting its influential role in the academic community. The Journal is aimed at researchers, mental health professionals, and students, promoting the dissemination of essential knowledge and innovative practices. Subscribers benefit from the latest findings and discussions in the field while contributing to the ongoing advancements in psychiatric care. Although not classified as open access, the journal ensures wide accessibility to its valuable content, further solidifying its commitment to the mental health discipline.

EXPERIMENTAL AND CLINICAL PSYCHOPHARMACOLOGY, published by the American Psychological Association, stands as a pivotal resource within the fields of pharmacology and psychiatry. With an ISSN of 1064-1297 and an E-ISSN of 1936-2293, this journal contributes significantly to the understanding of psychopharmacological interventions through its rich array of research articles, reviews, and clinical studies. Classified within the Q2 category in both Pharmacology and Psychiatry and Mental Health, it reflects a solid standing in academic performance, evidenced by its rankings in Scopus, where it places within the top half of its categories. Spanning from 1993 to 2024, it seeks to provide an essential platform for the dissemination of knowledge and advancements that influence clinical practice and therapeutic approaches. Although not an open-access journal, its impact on the development of evidence-based psychopharmacological treatments cannot be overstated, making it a vital resource for researchers, clinically active professionals, and students eager to stay abreast of cutting-edge developments in mental health and pharmacology.

Pharmakopsychiatry is a distinguished journal published by Georg Thieme Verlag KG that has been at the forefront of research since its inception in 1984. This peer-reviewed journal, with an ISSN of 0176-3679 and E-ISSN of 1439-0795, occupies a pivotal role in the field of medicine, focusing on the intricate intersections of pharmacology, psychiatry, and mental health. Its robust academic standing is demonstrated by its Q2 quartile rankings across multiple categories, including Medicine (miscellaneous) and Psychiatry and Mental Health, showcasing its significant influence with Scopus ranks placing it in the 80th percentile for Psychiatry and Mental Health. Pharmakopsychiatry aims to disseminate cutting-edge research that advances our understanding of pharmacological treatments in psychiatric practice, catering to a diverse audience of researchers, clinicians, and students. With an unwavering commitment to high-quality scholarship and its strategic location in Germany, this journal is an essential resource for those seeking to stay abreast of emerging trends and methodologies in the field.

BIPOLAR DISORDERS, published by Wiley, is a leading international journal dedicated to advancing the understanding and treatment of bipolar disorders. Since its establishment in 1999, the journal has become a vital resource in the fields of Biological Psychiatry and Psychiatry and Mental Health, currently ranked in the Q2 category for Biological Psychiatry and Q1 for Psychiatry and Mental Health as of 2023. With impressive Scopus rankings, it stands at 75th out of 567 in Psychiatry and Mental Health and 11th out of 51 in Biological Psychiatry, reflecting its influential role in shaping mental health research. The journal not only focuses on empirical studies, reviews, and clinical reports but also encourages innovative methodological advancements in understanding bipolar disorders. Although it does not offer Open Access, its extensive coverage from 1999 to 2024 ensures that practitioners, researchers, and students have access to a wealth of knowledge critical for the development of effective therapeutic interventions. For those engaging with cutting-edge research in psychiatric care, BIPOLAR DISORDERS serves as an essential platform for knowledge dissemination and academic discourse.

PSYCHIATRY AND CLINICAL NEUROSCIENCES is a leading journal in the fields of psychiatry and clinical neurology, published by Wiley. With a commendable impact factor and a position within the prestigious Q1 quartile across multiple relevant categories—including Medicine (Miscellaneous), Neurology, and Psychiatry and Mental Health—this journal stands out for its rigorous peer-reviewed content that addresses critical issues in mental health and neurological disorders. Established in 1933, the journal has a rich history of contributing impactful research that guides both clinical practice and academic inquiry. Although it is not an open-access journal, its high relevance is underscored by its Scopus rankings, with notable percentiles in Psychiatry and Neurology, making it a vital resource for researchers, clinicians, and students looking to stay abreast of the latest advancements. Located in the United Kingdom, PSYCHIATRY AND CLINICAL NEUROSCIENCES aims to bridge the gap between theory and practical application, fostering a comprehensive understanding of the complex interplay between mental health and neurological conditions.

PSYCHIATRIC QUARTERLY, published by Springer, stands as a pivotal resource in the field of psychiatry and mental health since its inception in 1927. With a reputable Q2 categorization in Psychiatry and Mental Health for 2023, this journal ranks impressively at #77 out of 567 in Scopus, placing it in the top 86th percentile of its category. Covering a diverse range of topics related to mental health, PSYCHIATRIC QUARTERLY aims to disseminate rigorous research findings, theoretical advancements, and clinical insights that contribute to improved mental health practices and policies. Although it does not offer open access, it provides substantial value to researchers, professionals, and students through its comprehensive analyses and scholarly articles. Located in New York, United States, the journal serves as an essential platform for advancing the understanding and treatment of psychiatric disorders, making it an invaluable addition to any academic library or research portfolio.

Obesity Research & Clinical Practice is an esteemed journal published by ELSEVIER SCI LTD, focusing on cutting-edge research and clinical practices related to obesity and its multifaceted impact on health and wellness. With an ISSN of 1871-403X and an E-ISSN of 1878-0318, this journal serves as a vital resource for researchers and practitioners in the fields of Endocrinology, Diabetes and Metabolism and Nutrition and Dietetics. Notably, it holds a Q2 ranking in Endocrinology, Diabetes and Metabolism and a prestigious Q1 ranking in Nutrition and Dietetics for 2023, reflecting its influence and quality within the scientific community. The journal features a broad scope of research topics encompassing clinical findings, epidemiological studies, and therapeutic advancements in obesity treatment, aiming to improve health outcomes globally. Submissions are encouraged from diverse disciplines, ensuring a dynamic and multidisciplinary approach to tackling obesity-related challenges. Given its convergence of years from 2007 to 2024, Obesity Research & Clinical Practice stands as a prominent platform for disseminating valuable knowledge, insights, and groundbreaking research in this pressing area of public health.

Therapeutic Advances in Psychopharmacology is a leading open-access journal published by SAGE Publications Ltd, focusing on the dynamic integration of pharmacological therapies and psychological health. Since its inception in 2011, this journal has made a significant impact on the fields of pharmacology and psychiatry, consistently earning a Q1 ranking in both categories as of 2023, reflecting its esteemed position within the scientific community. With an impressive Scopus rank placing it in the top 15% across relevant disciplines, the journal serves as a vital platform for researchers, professionals, and students eager to explore cutting-edge advancements in psychopharmacology. The open-access model, established in 2019, ensures that groundbreaking research is accessible to a wide audience, fostering collaboration and innovation in therapeutic strategies for mental health disorders. Through the dissemination of high-quality research and reviews, Therapeutic Advances in Psychopharmacology is committed to advancing understanding and practice within this critical field.

INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE is a distinguished publication in the field of Psychiatry and Mental Health, published by TAYLOR & FRANCIS LTD in the United Kingdom. With an impressive 2023 impact factor that places it in the Q2 category among its peers, this journal is an essential resource for researchers, clinicians, and students dedicated to advancing mental health practices and understanding psychiatric disorders. Covering topics from clinical studies to innovative treatment methodologies, the journal welcomes original research, reviews, and case studies that contribute valuable insights into clinical practice. Accessible without any open access restrictions, the journal has been a pivotal platform since its inception in 1997, facilitating knowledge exchange in the field up to 2024. As evidenced by its notable Scopus ranking within the top 73rd percentile of Psychiatry and Mental Health, it remains committed to impacting clinical practices significantly.

The Turkish Journal of Endocrinology and Metabolism, published by AVES, is a prominent platform dedicated to advancing research in the fields of endocrinology, diabetes, and metabolism. As an Open Access journal since 2002, it provides unrestricted access to its content, fostering a global exchange of knowledge among researchers, clinicians, and students. Operating from Turkey, this journal plays a crucial role in disseminating innovative findings related to endocrine disorders and metabolic diseases. While its current Q4 quartile rankings in both Endocrinology and Internal Medicine underscore areas for growth, they also signify the journal’s commitment to enhancing its impact within these disciplines. The journal emphasizes the development of locally relevant research while encouraging international contributions, thus bridging gaps in global health discourse. Engage with cutting-edge research that shapes clinical practices and informs public health policies by submitting your work or exploring the journal’s vast archive from 2009 to 2023.